Cancer rates in 2025 are predicted to exceed the previous year's statistics, with one-in-three men and women both at risk of ...

Starting oral risdiplam soon after birth may put babies with spinal muscular atrophy on the path to normal development, new ...

Bicycle Therapeutics is reducing its headcount by around 25% to extend its cash runway into 2028. | Bicycle Therapeutics is ...

With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...

Roche’s Genentech has reported new five-year data from the Phase III Portal trial, confirming the safety, durability, and ...

Here, we provide a compilation of some of the rising stars of separation science, detailing their ongoing contributions to the industry.

Q2 2025 Earnings Call Transcript August 12, 2025 Lineage Cell Therapeutics, Inc. misses on earnings expectations. Reported ...

Genentech's Portal study shows Susvimo maintains vision and retinal drying in wet AMD patients over five years with biannual ...

Despite its potential, incorporating new treatments like T-DXd into a first-line setting faces several barriers, explains Michael Hassett, MD, MPH, chief quality officer at Dana-Farber Cancer ...

GAAP revenue doubled in Q2 2025 compared to Q2 2024, significantly beating analyst expectations on a GAAP basis as Collaboration income (GAAP) also doubled compared to Q2 2024. Net loss (GAAP) ...

Trump targets 2 big Bay Area drugmakers in 'most favored nation' drug-pricing decree ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...